Cargando…
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
BACKGROUND: The Scottish Medicines Consortium evaluates new drugs for use in the National Health Service in Scotland. Reforms in 2014 to their evaluation process aimed to increase patient access to new drugs for end-of-life or rare conditions; the changes include additional steps in the process to g...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577765/ https://www.ncbi.nlm.nih.gov/pubmed/28854927 http://dx.doi.org/10.1186/s12913-017-2561-0 |